Regulatory and Compliance Updates news

• 

  20 March 2026

  Petrobras resumes investments in Minas Gerais during Lula visit

  During Lula’s visit to Regap (Betim), resumption of investments announced: R$3.8bn (2026–30), up to R$9bn/10 yrs; 8k–36k jobs; +25k bpd capacity (2027) and 13.3 MW solar plant.
• 

  19 March 2026

  FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial

  Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
• 

  19 March 2026

  Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss

  STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
• 

  19 March 2026

  GSK: Lynavoy (linerixibat) FDA-approved for cholestatic pruritus in PBC

  FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.
• 

  19 March 2026

  Clariant opens pharma-grade PEG manufacturing plant in Texas

  GMP-compliant excipient production strengthens supply-chain resilience, shortens lead times, and improves continuity and traceability for pharma customers across North & Latin America.
• 

  19 March 2026

  Equinor Annual Report 2025

  Record production and strong cash results in 2025; safety improved; adjusted operating income $27.6B; production 2,137 mboe/d; renewables +25%; emissions −34% since 2015.

• 

  18 March 2026

  Petrobras Contracts 8 Thermoelectric Plants in 2026 Capacity Reserve Auction

  Result secures ~R$4bn annual fixed revenue, requires signing CRCAPs, proving firm fuel supply and meeting ONS operational rules; portfolio totals 4.9 GW, supporting SIN availability
• 

  18 March 2026

  Eni 2025 Financial Statements

  Board approved 2025 Annual Report: consolidated net profit €2,608m, parent €4,429m. 4th dividend scheduled (ex-div May 18, pay May 20). AGM May 6; governance, sustainability and remuneration reports to be published.
• 

  18 March 2026

  Johnson & Johnson FDA approves ICOTYDE (icotrokinra) for first‑line systemic treatment of plaque psoriasis

  First targeted oral IL‑23 receptor peptide approved for moderate‑to‑severe plaque psoriasis in adults and ≥12 (≥40kg). Once‑daily pill; ~70% IGA0/1, 55% PASI90 at Week16; safety like placebo.
• 

  18 March 2026

  Boliden invests SEK 4bn in Garpenberg hoist and SEK 1.5bn in Rönnskär SCM plant

  SEK 4bn hoist at Garpenberg to keep 4.5 Mt/yr past 2030; SEK 1.5bn Rönnskär demo plant (280 kt/yr SCMentum) 2026–28. SCM emits <5% of cement CO2; exploration continues.
• 

  18 March 2026

  Avantium reports 2025 full-year results

  Phased start-up of the FDCA Flagship Plant progressed despite construction delays; €85M equity and amended financing secured; half the plant operational; full start-up targeted in 2026
• 

  17 March 2026

  Vioneo on the EU Single‑Use Plastics Directive

  Calls for SUPD to clarify treatment of fossil-free plastics, align rules with decarbonisation goals, harmonise EPR and fee eco-modulation, and incentivise renewable-carbon supply chains.
• 

  17 March 2026

  Kemira obtains PMRA approval in Canada for KemConnect DEX

  Chlorine-free performic-acid wastewater disinfection; used in Paris 2024 wastewater works. Combines on-site generation, real-time monitoring and dosing algorithm. Canada rollout pending approvals
• 

  16 March 2026

  Terumo Aortic's Fenestrated TREO® Gains FDA Breakthrough Status

  The FDA's Breakthrough Device Designation accelerates the review of Fenestrated TREO®, a custom stent-graft for complex abdominal aortic aneurysms, offering a tailored, minimally invasive solution.
• 

  16 March 2026

  Petrobras to Acquire Full Ownership of Tartaruga Verde and Espadarte Fields

  Petrobras will pay $450M to acquire Petronas' 50% stake in Tartaruga Verde and Espadarte fields, regaining full ownership. Completion awaits regulatory approval.
• 

  16 March 2026

  Aptar's Nasal Delivery System in Phase II Study for SPONTAN® Spray

  Aptar's nasal system aids LTR Pharma's SPONTAN® Phase II study, focusing on safety, tolerability, and pharmacokinetics for erectile dysfunction treatment.
• 

  16 March 2026

  Neste Advocates Strong Anti-Fraud Measures in Biofuels Supply Chains

  Neste emphasizes rigorous supplier audits, traceability, and collaboration to combat fraud in renewable raw materials, ensuring compliance and authenticity in its supply chains.
• 

  16 March 2026

  Lilly's EBGLYSS Achieves Positive Phase 3 Results in Pediatric Atopic Dermatitis

  EBGLYSS shows significant skin improvement and itch relief in children with moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints in Phase 3 ADorable-1 trial.
• 

  13 March 2026

  MOL and Slovnaft File Complaint Against JANAF's Pricing Practices

  JANAF's pricing is deemed excessive and unjustified, impacting energy supply security. MOL and Slovnaft have raised concerns with the European Commission over these practices.
• 

  13 March 2026

  Petrobras Adjusts Diesel Prices

  Diesel prices rise by R$ 0.38/liter for distributors. Federal tax exemptions and a subsidy program mitigate consumer impact.
• 

  13 March 2026

  GSK's Arexvy RSV Vaccine Approved for Expanded Use in US Adults 18-49

  FDA expands Arexvy's use to adults 18-49 at risk for severe RSV. Phase III trials show efficacy and safety. 17,000 hospitalizations annually in this age group.
• 

  13 March 2026

  Petrobras Joins Diesel Subsidy Program

  Petrobras' Board approves joining a diesel subsidy, pending regulatory review. The move aligns with its strategy to maintain market share and profitability without price volatility.
• 

  12 March 2026

  Lhyfe Maintains Strong ESG Rating from Ethifinance

  Lhyfe scored 88/100 in 2024 ESG performance, reflecting strong environmental efforts and energy independence, with improved ratings since 2022.
• 

  12 March 2026

  Johnson & Johnson's TECNIS PureSee IOL Gains FDA Approval for Cataract Surgery

  TECNIS PureSee IOL offers enhanced vision for cataract patients, reducing reliance on glasses and maintaining contrast sensitivity, with 97% reporting no bothersome visual disturbances.
• 

  11 March 2026

  Port of Rotterdam: Demand Uncertainty Delays Hydrogen Terminal Investments

  Investment in hydrogen terminals is stalled due to demand uncertainty, policy clarity, grid congestion, and infrastructure issues, with operations expected post-2030.
• 

  10 March 2026

  BASF Expands Ultrason® P Portfolio for EU Food-Contact Compliance

  Six new PPSU grades comply with EU regulations, enabling a smooth transition for manufacturers of high-temperature food-contact articles.
• 

  9 March 2026

  Shell Sells Jiffy Lube and Premium Velocity Auto to Monomoy Capital Partners

  Shell sells Jiffy Lube and Premium Velocity Auto for $1.3B, retaining other lubricant brands. A long-term supply agreement is included. Closing expected in H2 2026, pending approvals.
• 

  9 March 2026

  Sinopec Leads Hydrogen Standardization in Energy Industry

  A new committee aims to enhance hydrogen industry standards, drive innovation, and regulate the market, marking a key step for China's hydrogen energy sector.
• 

  9 March 2026

  GSK and Alfasigma License Agreement for Linerixibat Rights

  Alfasigma gains global rights to develop and market linerixibat for cholestatic pruritus in PBC. GSK to receive payments and royalties. Regulatory reviews are ongoing.
• 

  8 March 2026

  Genentech Updates on Phase III persevERA Study in ER-Positive Breast Cancer

  persevERA study showed no significant progression-free survival improvement, but giredestrant was well tolerated. Further studies planned with CDK4/6 inhibitors.